Katherine Seley-Radtke

​

Contact Information
Office: CHEM 405C
Phone: 410-455-8684

Professor

Post-Doctoral Auburn University 1996; Ph.D. Auburn University 1996; B.A. University of South Florida 1992

Professional Interests

Current Fields of Interest:

Medicinal/Synthetic Bioorganic/Organic Chemistry and Drug Design: Discovery, design and synthesis of nucleoside/nucleotide and heterocyclic enzyme inhibitors with chemotherapeutic emphasis in the areas of antiviral, anticancer, antibiotic, and antiparasitic targets. Primary goals include development of potent inhibitors to shut down disease replication pathways through a combination of cross-disciplinary synthetic, biological screening, mechanistic, and structure-based drug design techniques.

The primary focus for the Seley-Radtke laboratories involves the design and synthesis of flexible nucleoside (“fleximers”) and nucleobases (“flex-bases) inhibitors as a powerful approach to overcome the development of resistance to currently used therapeutics. The fleximers are able retain full potency when faced with “escape mutations” in biologically critical enzymatic systems – the inherent flexibility of the inhibitors allows them to conformationally adjust to steric and electronic clashes encountered in the binding site, and to engage secondary amino acids not previously involved in the enzyme’s mechanism of action.

Potent activity has been reported for a series of “doubly flexible” acyclic nucleosides and their corresponding prodrugs against various viruses including coronaviruses such as SARS-1, MERS-CoV, and most recently SARS-CoV-2 and COVID. Importantly, the corresponding parent nucleosides, for example, Acyclovir, have shown no activity against any of those viruses. Not only does this observation provide strong impetus that the fleximer technology can be a powerful tool for developing more effective inhibitors, but also provides an important broad-spectrum approach that is critical to overcoming viral variants and new emerging strains. Other targets currently under investigation with both the acyclic, as well as various 2’-deoxy and ribose-based scaffolds, include filoviruses such as Ebola and Marburg, and flaviviruses such as tickborne encephalitis, Dengue and Yellow Fever, among other high priority neglected diseases.

In addition to viral targets, another project focuses on the use of nucleobases as anticancer agents. For example, the potent activity exhibited by gemcitabine, Ara-C and other related FDA-approved anticancer analogues, has led to numerous structural modifications designed to increase target specificity and potency. Following upon the recent observation that several nucleobase analogues including thiophene-expanded purines, as well as pyrrolo – and thienopyrimidines designed in our laboratories have exhibited selective and highly potent (sub-nanomolar) levels of activity against several key cancers including lung, colon, leukemia, renal, and triple negative breast cancers (among others), we have initiated a program to elucidate their mechanism of action, as well as to further study their highly promising activity in vitro and in vivo. These compounds have advanced to animal studies and as well as investigations to elucidate their mechanism of action.

All of the projects being pursued in the Seley-Radtke laboratories employ structure activity relationship (SAR) algorithms for the biological enhancement of lead compounds. Intimately related to the goals of the drug design projects, synthetic organic chemistry includes the discovery of unique strategies to solve design challenges using state of the art techniques for the construction of modified heterocycles, carbohydrates and carbocyclic moieties. In addition, we utilize a cross-disciplinary chemical biology approach in partnership with our various collaborators around the world to determine the effectiveness of the potential drug candidates, as well as to investigate enzyme fidelity with our unique analogues that possess strategic structural advantages for enhanced molecular recognition.

Publications

 Publications (Last 3 Years)

  1. Khandazhinskaya, A.; Eletskaya, B.; Fateev, I.; Kharitonova, M.; Konstantinova, I.; Barai, V.; Azhaev, A.; Hyvonen, M.; Keinanen, T.; Kochetkov, S.; Seley-Radtke*, K.; Khomutov, A.; Matyugina, E. “Novel fleximer pyrazole-containing adenosine analogues: chemical and biotechnological synthesis” 2021, Org Biomol Chem, DOI: 10.1039/d1ob01069g.
  2. Eyer, L.; Svobodfa, P.; Balvan, J.; Vičar, T.; Raudenska, M.; Stefánik, M; Haviernik, J.; Huvarová, I.; Straková, P.; Hubálek, Z.; Seley-Radtke, K. L.; de Clercq, E.; Růžek, D. “Broad-spectrum antiviral activity of 3´-deoxy-3´-fluoroadenosine against emerging flaviviruses”, 2021, Antimicrob Agents Chemoth; 5:e01522-20.https://doi.org/10.1128/AAC.01522-20.
  3. Thames, J. E.; Waters III, C. D.; Valle, C.; Bassetto, M.; Aouadi, W.; Martin, B.; Falat, A.; Coutard, B.; Brancale, A.; Canard, B.; Decroly, E.; *Seley-Radtke, K. L. “Synthesis and Biological Evaluation of Novel Flexible Nucleoside Analogues that Inhibit Flavivirus Replication In Vitro” Bioorg Med Chem 2020, 28, 115713.
  4. Vichier-Guerre, S.; Ku, T.; Pochet, S.; Seley-Radtke, K. L.* “An expedient synthesis of flexible nucleosides through enzymatic glycosylation of proximal and distal fleximer bases”, ChemMedChem, 2020, 21, 1412-1417 (featured article and cover).
  5. Matugina, E. S.; Khandazhinskaya, A. L.; Kochetkov, S. N. *Seley-Radtke, K. L. “Synthesis of Pyrrole-Containing Heteroaromatic Compounds by Suzuki-Miyaura Cross-Coupling” Mendeleev Communications 2020, 30, 231-231.
  6. Yates, M. K.; Chatterjee, P.; Flint, M.; Arefeayne, Y.; Plavec, J.; Spiropoulou, C. F.; *Seley-Radtke, K. L.; “Probing the Effects of Pyrimidine Functional Group Switches on Acyclic Fleximer Analogues for Antiviral Activity” Molecules: Discovery, Design, Synthesis, and Application of Nucleoside/Nucleotides” 2019, 24, 3184-3197, doi.org/10.3390/molecules24173184.
  7. Khandazhinskaya, A. L.; Matyugina, E. S.; Solyev, P. N.; Wilkinson, M.; Buckheit, K. W.; Buckheit Jr., R. W.; Chernousova, L. N.; Smirnova, T. G.; Andreevskaya, S. N.; Kochetkov, S. N.; De Koning, H. P.; *Seley-Radtke, K. L. “Biological Investigations for a Series of Carbocyclic Nucleoside Analogues as Antibacterial Agents”, Molecules: Discovery, Design, Synthesis, and Application of Nucleoside/Nucleotides” 2019, 24(19), 3433-3448, doi:10.3390/molecules24193433.
  8. Cawrse, B. M.; Robinson, N. M.; Lee, N. C.; Wilson, G. M.; *Seley-Radtke, K L.; Structural and biological Investigations for a series of N-5 substituted pyrrolo[3,2-d]pyrimidines as potential anticancer therapeutics. Molecules: Bioactive Nucleosides and Nucleotides 2019, 24, 2656-68; doi:10.3390/molecules24142656.
  9. Ku, T.; Lopresti, N.; Shirley, M.; Mori, M.; Marchant, J.; Heng, X.; Botta, M.; Summers, M. F.; *Seley-Radtke, K. L. Synthesis of Distal and Proximal Fleximer Base Analogues and Evaluation in the Nucleocapsid Protein of HIV-1. Bioorganic Med Chem; 2019, 27, 2883-92.
  10. Yates, M. and *Seley-Radtke, K. L., “The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part II: complex modifications to the nucleoside scaffold” Antiviral Res. 2019, 162, 5-21. Highlighted article.
  11. Khandazhinskaya, A. L.; Alexandrova, L.A.; Matyugina, E. S.; Solyev, P. N.; Efremenkova, O. V.; Buckheit, K. W.; Garvey, M.; Buckheit Jr, R. W.; Chernousova, L. N.; Smirnova, T. G.; Andreevskaya, S. N.; Leonova, O. G.; Popenko, V. I.; Kochetkov, S. N.; *Seley-Radtke, K. L. “Novel 5’-Norcarbocyclic Pyrimidine Derivatives” as Antibacterial Agents, Molecules, 2018, 23, 3069-87.
  12. *Seley-Radtke, K. L. and Yates, M. “The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part I: early structural modifications to the nucleoside scaffold.” Antiviral Res. 2018, 154, 66-86. Highlighted article.
  13. Temburnikar, K.; *Seley-Radtke, K. L.; “Recent advances in synthetic approaches to C-nucleosides”, Beilstein J Org Chem 2018, 14, 772-785.
  14. *Seley-Radtke, K. L. “Flexibility – not just for Yoga!” Antiviral Chem Chemoth, 2018, 26, 1-12. Highlighted article.
  15. Eyer, L.; Nencka, R.; de Clercq, E.; Seley-Radtke, K.L.; Růžek, D. “Nucleoside analogues as a rich source of antiviral agents against arthropod-borne flaviviruses”, Antiviral Chem Chemother 2018, 26, 1-28.
  16. Cawrse, B.M.; Lapidus, R.S.; Cooper, B.; Choi, E. Y.; *Seley-Radtke, K.L.; “Antiproliferative Effects of Halogenated Pyrrolo[3,2-d]pyrimidines with Decreased Toxicity Via N5 Substitution.” ChemMedChem 2018, 13, 178-185.

 

Invited (Peer-reviewed) Book Chapters

1. Ku, T. C.; *Seley-Radtke, K. L. “Design and Synthesis of Fleximers. A Novel Class of
Structurally Diverse Nucleosides”, in “New Trends in Enzymatic and Chemical synthesis of
Nucleic Acid Derivatives”, Jesús Fernández-Lucas and María-José Camarasa Rius eds.
Wiley-VCH, Weinheim, Germany, 2019, Chapter 8, 195-255.
2. Zimmermann, S. C.; *Seley-Radtke, K. L. "Flexible nucleobase analogues. New tools for
nucleic acid discoveries", in RNA Technologies: DNA and RNA Chemical Biology in Science
and Medicine, V. A. Erdmann, W. T. Markiewicz and J. Barciszewski eds. Springer, NY, NY
2014, pp 149-165.
3. *Seley, K. L.; Mosley, S. L. "Purine Analogues and Their Role in Methylation and Cancer
Chemotherapy" in DNA Methylation and Cancer Therapy, Moshe Szyf, Ed. Landes
Bioscience, Georgetown, TX, 2004, Chapter 13, pp 178-186.
4. *Seley, K. L. "Tricyclic Nucleosides Revisited" in Recent Advances in Nucleosides:
Chemistry and Chemotherapy, pg. 299-326, C.K. Chu, Ed. Elsevier Science, 2002.
5. Schneller, S. W.; Seley, K. L.; Hegde, V. R.; Rajappan, V. P. "5′-Norcarbanucleosides in L-
Like Configurations" in Recent Advances in Nucleosides: Chemistry and Chemotherapy, pg.
291-297; C.K. Chu, Ed. Elsevier Science, 2002.

Professional Experience

Higher Education

2021-present   Wayne State University, NIH FIRST program, External Advisory Board member

2019-present   Pennsylvania State University, NIH T32 Chemistry Biology Interface Graduate Training Program Advisory Board

2017                Distinguished Visiting Professor, Université d’Orléans, Orléans, France

2017-2018       University System of Maryland Regents’ Professor for Excellent in Research

2015-2018       UMBC Presidential Research Professor

2015-2016       Chair, University Faculty Promotion and Tenure Review Committee (UFRC)

2011-present   Professor, Chemistry & Biochemistry, UMBC, & Joint UMB Biochemistry program

2010-present   Auburn University COSAM Advisory Council member

2009-present   UMBC Honors College Advisory Board member

2008-2010       UMBC Honors Program Faculty Fellow

2007-present   NIH Chemistry Biology Interface Graduate Program, Director and mentor

2007-2008       UMBC President’s Commission on Women, Faculty representative

2005-present   Program in Oncology, Greenebaum Cancer Center, Faculty Member

2005-present   Auburn University Society of Women in Sciences & Mathematics Board Member

2004-2006       UMBC Graduate Summer Bridge Program, Founder & Inaugural Director

2003-present   NIH/UMBC Meyerhoff Minority Graduate & Undergraduate Faculty mentor

2003-present   NSF UMBC MARC U*STAR program, Faculty mentor

2003-2004       NSF UMBC EMBARC (REU) Program, Program Director

2003-2011       Associate Professor, Chemistry & Biochemistry, UMBC

1998-2003       Assistant Professor, Chemistry & Biochemistry, Georgia Institute of Technology

1997-98           Visiting Assistant Professor, Auburn University

1996-98           Postdoctoral Research Fellow, Auburn University

Other than Higher Education:

2022-present   Editor in Chief, Annual Reports in Medicinal Chemistry (beginning Oct 2022)

2022-2024       President, International Society for Antiviral Research (ISAR)

2022-present   Associate Editor, Science Advances/AAAS

2020-2022       President-elect, International Society for Antiviral Research

2021-present   Scientific and Clinical Advisory Board, Antios Therapeutics

2021                Chair, NIH review panel, AIDC-B, July 22-23

2021                Chair, NIH review panel – Topics in Coronavirus Drug Discovery and Development [2021/05 ZRG1 AIDC-K (83)], March 31-April 1

2021                Louisiana Board of Regents Chemistry Enhancement review panel

2020-present   Chair, ICAR Program committee, ISAR

2020-present   CEO and President, Flexivir Biosciences LLC

2020-2023       Co-Chair, Gordon Research Conference on Nucleosides, Nucleotides &     Oligonucleotides

2020                Chair, NIH review panel – Emergency Awards: Rapid Investigation of Severe Acute      Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19), July 17; Dec 28-29

2020                Co-Chair, NIH review panel – Antimicrobial Therapeutics and Resistance, March 19-20,       July 8-9, Oct 11-12

2020-2022       Editorial Board, Annual Reports in Medicinal Chemistry

2020-present   Advisory Board, American Council on Science and Health

2020                NIH Review panel: ZRG1 BCMB-A; NIH Transformative Research Awards, April 7

2019-present   Gordon Research Conference Council, member

2018-2019       Co-Vice Chair, Gordon Research Conference on Nucleosides, Nucleotides &      Oligonucleotides, June 23-29, 2019

2019-2023       Secretary, International Society of Nucleosides, Nucleotides & Nucleic Acids (IS3NA)

2019     NIH Review panel – Antimicrobial Therapeutics and Resistance – Co-Chair, March 25-26, June 3-4 and Nov 7-8, July 31 (Chair)

2019      Session Chair, Advances in Noncanonical Nucleic Acids, Rogaška Slatina, Slovenia, Oct 17-19.

2019    Session Chair, Gordon Research Conference on Nucleosides, Nucleotides &            Oligonucleotides, June 23-29

2019                NIH ZRG1 IMM-R(50) U.S.-Brazil Collaborative Biomedical Research Program, ad hoc reviewer, July 16

2019                Session Chair, 32nd International Conference on Antiviral Research, Baltimore, May 12-15th, 2019.

2019                NIH Review panel – Antimicrobial Therapeutics and Resistance – Co-Chair, March 25-26, June 3-4, and Nov 7-8; July 31 (Chair)

2018                Session Chair, Advances in Noncanonical Nucleic Acids, Portorož, Slovenia, Oct 25-27.

2018                Session Chair and Co-organizer, XXIII International Roundtable on Nucleosides, Nucleotides & Nucleic Acids, San Diego, August 26-30

2018                Session Chair, 31st International Conference for Antiviral Research (ICAR), Porto, Portugal, June 11-15

2018                NIH Special Emphasis Panel – Antimicrobial Therapeutics and Resistance – ZRG1 IDM-Y (82) and 2018/05 ZRG1 IDM-T (07)S, March 28-29, June 28-29, Nov 15-16

2018                Session Chair, 7th European Workshop in Drug Synthesis, Siena, Italy, May 24

2018-present   Section Editor, Molecules – Chemical Biology

2018                Special Collections Editor, “Advances in Antiviral Nucleoside Analogues and Their Prodrugs“, Antiviral Chemistry & Chemotherapy

2017                NIH Special Emphasis Panel – Antimicrobial Therapeutics and Resistance ZRG1 IDM-Y (82), Nov 2-3

2017                NIH/NCI ZCA1 SRBK NCI Clinical and Translational R21 & Omnibus R03 review panel, Vice Chair, June 13-14

2017-2018       Immediate Past President, International Society for Nucleosides, Nucleotides & Nucleic Acids (IS3NA)

2017-2018       Chair, Nominations Committee, IS3NA

2017-present   Chair, The Chu Family Foundation awards, International Society of Antiviral Research (ISAR)

2017                Session Chair, Gordon Research Conference on Nucleosides, Nucleotides & Oligonucleotides, Salve Regina University, Newport, RI, June 25-30

2017                Session Chair, 30th International Conference on Antiviral Research, Atlanta, GA, May 21-25

2016-present   Associate Editor, Antiviral Chemistry & Chemotherapy

2016                NIH/NIGMS ZGM1 TRN-Y, Maximizing Investigators Research Awards (MIRA) review panel, Nov 10-11

2016                NIH ZAI1-JRR-M-J3 Rapid Assessment of Zika Virus (ZIKV) Complications review panel, ad hoc member and vice chair, Oct 20

2016                NIH AIDS Discovery & Development of Therapeutics (ADDT) study section, ad hoc member, July 26

2016                NIH F04A-Y(20)L T31/T32 Fellowship study section, ad hoc member, July 13

2016                Session Chair, XXII International Roundtable on Nucleosides, Nucleotides & Nucleic Acids, Paris, France, July 18-21

2016                Session Chair, 6th European Workshop in Drug Synthesis, Siena, Italy, May 17

2016                Session Chair, 5th Antiviral Drugs Research & Development, San Diego, June 1

2016                Conference Committee, 29th International Conference on Antiviral Research, San Diego, CA

2016                Session Chair, 29th International Conference on Antiviral Research, San Diego, CA, April 19

2015-2016       President, International Society on Nucleosides, Nucleotides & Nucleic Acids (IS3NA)

2016-2018       Board of Directors, International Society for Antiviral Research (ISAR)

2016-present  Chair, The Chu Family Women in Science Awards Committee, ISAR

2016-present   Chair, The Chu Family Early Career Awards Committee, IS3NA

2015                NIH/NIGMS ZGM1 TRN-Y, Maximizing Investigators Research Awards (MIRA) review panel

2015-present   Women in Science Scholarship Committee, ISAR

2015-present   UMBC Meyerhoff Program Advisory Board

2015                NIH/NCI ZCA1 SRB-2 Drug Development & Targeting Special Emphasis Panel, Acting Chair

2015                Session Chair, 10th European Workshop in Drug Design, Siena, Italy, May 18-22

2105                Session Chair, 28th International Conference on Antiviral Research, Rome, Italy, May 11-15

2014                Session Chair, 21st International Roundtable on Nucleosides, Nucleotides & Nucleic Acids, August 24-28, Poznan, Poland

2014-present   Program Committee, ISAR

2014                Broadening Experiences in Scientific Training, Advisory Board member, University of Notre Dame Ph.D. program

2014                Session Chair, National ACS Medicinal Chemistry Symposium, Charleston, SC, May 18, 2014

2014                Session Chair, 27th International Conference on Antiviral Research (ICAR), Raleigh, May 12-15

2014                NIH ZRG1 AARR-J PAR Panel: Sustained Release of Antivirals for Treatment or Prevention of HIV, Acting Chair

2013-present   Women in Chemistry Committee, ISAR

2013-2016       Board of Directors, ISAR

2013                NIH/NCI ZCA1 SRLB-2 Exploratory/Developmental Research study section

2013-2014       Vice President, IS3NA

2013-2014       Co-organizer, National ACS Medicinal Chemistry Symposium, Charleston, SC, May 18-21, 2014

2013-2014       Session Chair, National ACS Medicinal Chemistry Symposium, Charleston, SC, May 18-21, 2014

2013-2017       Award Nomination & Selection Committee, ACS Medicinal Chemistry Division

2013                Session Chair, 26th ICAR, San Francisco, May 10-16

2012-2017       ISAR Poster Award Committee Chair

2012-present   Editorial Board, Clinical Medicine Insights, Therapeutics

2012                Med Chem Session Chair, 244th National ACS meeting, Philadelphia, PA

2012                Session Chair, 4th European Workshop in Drug Synthesis, May 28, Siena, Italy

2012                Med Chem Session Chair, 243rd National ACS meeting, San Diego, CA

2012                NIH ZRG1 Member Conflict study section (ad hoc)

2011-2013       Editorial Board, Research and Reports in Medicinal Chemistry

2011                Med Chem Session Chair, 242nd National ACS meeting, Denver, CO.

2011                Session Chair, 8th European Workshop in Drug Design, May 22-28, Siena, Italy

2011-present   Associate Editor, Current Protocols in Chemical Biology

2010-2014       NIH AIDS Discovery & Development of Therapeutics (ADDT) study section, member (Vice Chair – 2013-2014)

2010-2012       ACS Div. of Med. Chem. Long Range Planning Committee

2007-2012      Secretary, IS3NA

2010                Session Chair, 19th International Roundtable on Nucleosides, Nucleotides & Nucleic Acids, August 29-Sept 3, 2010, Lyon, France

2009                NSF Chemical Synthesis study section

2008-present   NAS Jefferson Science Fellowship Selection Committee

2008-2012       Scientific Advisory Board, Deszyme Inc.

2008                Session Chair, 12th Indian Society of Chemists & Biologists Int. Conf. on “The Interface of Chemistry-Biology in Biomedical Research“, Pilani, India

2007-2016       U.S. Embassy, Moscow Russia, Senior Science Advisor

2007                Women in International Security (WIIS) workshop “Science, Technology and U.S. National Security: Engaging the Next Generation” invited panel member and discussion leader, Washington, DC

 

2006-present   NAS Jefferson Science Fellow, U.S. Department of State

2005-2010       NIH/NIGMS Biomedical Research Training-A and-B study sections member

2005-present   IS3NA, Membership (Chair), Publications & website committees

2005-present   ISAR, Career Development Committee, Poster Awards Committee

2004-2008       Merck/AAAS Undergraduate Science Research Program (USRP) Selection Committee Member

2004                NIH Tropical Medicine & Parasitology Study Section member (ad hoc)

2004                Session Chair, International Roundtable on Nucleosides, Nucleotides and Nucleic Acids, Minneapolis, MN

2003                NIH Tropical Medicine & Parasitology Study Section member (ad hoc)

2003                Session Chair, Gordon Research Conference, Purines, Pyrimidines & Related Substances, Newport, RI

2002               NIH Bioorganic & Natural Products Study Section member (ad hoc)

2002                NIH BNZP Bioengineering Study Section member (ad hoc)

Honors, Awards, and Distinctions:

2021                Baltimore Sun’s 2021’s 25 Women to Watch

2020                International Society for Antiviral Research (ISAR) Antonín Holý Memorial Award

2017                USM Regents’ Faculty Award for Excellence in Research

2016                Maryland Chemist of the Year, American Chemical Society

2015-2018       UMBC Presidential Research Professor

2015                Outstanding Chemistry Alumni Award, University of South Florida

2011                Outstanding Faculty Member of the Year, UMBC Honors College students

2008-2010       Inaugural Faculty Fellow, UMBC Honors College Program

2006                NAS Jefferson Science Fellow, U.S. Department of State

2006                Distinguished Faculty Award, The National Society of Collegiate Scholars

2003                ACS PROGRESS Lectureship in Chemical Sciences Award

2002                “Class Of 1940 W. Howard Ector Outstanding Teacher” Georgia Institute of Technology  ($10,000 prize)

1998                Outstanding Faculty Award, Cardinal Key Honor Society, Auburn University

1997                Sigma Xi Outstanding Dissertation, Auburn University

1997                Carolyn Taylor Carr Award, Auburn University

1992                American Association of University Women Scholarship, U. of South Florida

1992    Hugh Culverhouse Outstanding Graduate Student Award, U. of South Florida

Courses Taught

  • CHEM 299: Training in Experimental Chemistry (Cooperative Education)
  • CHEM 351: Organic Chemistry I
  • CHEM 351L: Organic Chemistry Laboratory I
  • CHEM 352: Organic Chemistry II
  • CHEM 352L: Organic Chemistry Laboratory II
  • CHEM 399: Tutorial Projects in Chemistry
  • CHEM 450: Chemistry of Heterocyclic Compounds
  • CHEM 453: Organic Chemistry of Nucleic Acids
  • CHEM 455: Introduction to Biomedicinal Chemistry
  • CHEM 490: Special Topics in Chemistry – Organic Synthetic Methology
  • CHEM 499: Undergraduate Research
  • CHEM 600: Advanced Laboratory Projects
  • CHEM 602: Introduction to Laboratory Research
  • CHEM 650: Chemistry of Heterocyclic Compounds
  • CHEM 653: Organic Chemistry of Nucleic Acids
  • CHEM 654: Organic Synthetic Methodology
  • CHEM 655: Introduction to Biomedicinal Chemistry
  • CHEM 713: Biochemistry/Chemistry Seminar
  • CHEM 715: Issues at the Chemistry/Biology Interface
  • CHEM 898: Pre-Candidacy Doctoral Research
  • CHEM 899: Doctoral Dissertation Research